Profitability Metrics

Gross Margin
56.88%
Operating Margin
-43.12%
Net Margin
88.05%

Efficiency Metrics

Revenue per Expense Ratio
1.00
R&D as % of Revenue
0.00%

Earnings Quality

EBITDA Margin
247.26%
Income Tax Rate
0.00%
EPS
0.4400000000

Balance Sheet Analysis

Current Ratio
4.45
Cash Ratio
35.77
Working Capital
$5.36M
Debt to Equity
0.68
Debt to Assets
40.46%
Equity Ratio
59.24%

Cash Flow Analysis

Operating Cash Flow Ratio
322.87%
Free Cash Flow Ratio
322.87%
CapEx to Revenue
0.00%
Dividends Paid
$32.84M
Stock Buybacks
No buybacks
Total Shareholder Returns
$32.84M
Cash Position Change
4,233.8%

Key Takeaways (2023 FY)

  • Maintained positive net income growth despite revenue changes
  • Increased R&D investment by 100.00%

Detailed Growth Metrics

Core Performance

Revenue
111.94%
Net Income
110.36%
EPS
110.45%
Operating Income
94.54%

Operational Efficiency

R&D Expenses
100.00%
SG&A Expenses
-3.15%
Operating Cash Flow
33.76%
Free Cash Flow
33.76%

Balance Sheet Health

Assets
-3.32%
Debt
0.00%
Book Value per Share
-5.58%
Inventory
0.00%

Shareholder Returns

Dividends per Share
-4.82%
Shares Outstanding
0.00%

Long Term Trends

3Y Revenue/Share
-77.55%
5Y Revenue/Share
135.02%
3Y Dividend/Share
-11.00%
5Y Dividend/Share
-10.69%